Richard Miller, MD
Pulmonary Disease · Newark, NJNPI 1124109319
Payments from drug & device makers
Across 909 payments — averaging $360.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$297K
- Boehringer Ingelheim$25K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Insmed, Inc.$366
- Mylan Specialty L.p.$345
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$306,82594%
- Travel & lodging$2,2241%
- Food & beverage$18,3316%
- Education$5320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 436 | $296,891 |
| Boehringer Ingelheim | 108 | $24,519 |
| AstraZeneca | 111 | $1,875 |
| Actelion Pharmaceuticals US, Inc. | 59 | $1,177 |
| Insmed, Inc. | 26 | $366 |
| Mylan Specialty L.p. | 20 | $345 |
| Sanofi | 17 | $283 |
| Regeneron Healthcare Solutions, Inc. | 15 | $279 |
| United Therapeutics Corporation | 14 | $240 |
| Gilead | 10 | $215 |
| Sunovion Pharmaceuticals Inc. | 12 | $193 |
| Sanofi-aventis U.S. LLC | 2 | $183 |
| Genentech USA, Inc. | 4 | $172 |
| Teva Pharmaceuticals USA, Inc. | 12 | $162 |
| Johnson & Johnson | 9 | $116 |
| Philips North America LLC | 7 | $111 |
| Amgen | 4 | $87 |
| Bayer | 6 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $86 |
| Pfizer | 4 | $56 |
| Medtronic | 1 | $50 |
| Merck | 3 | $49 |
| Pulmonx Corporation | 2 | $46 |
| Mallinckrodt Enterprises LLC | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| Viiv Healthcare Company | 1 | $29 |
| AbbVie | 2 | $28 |
| Shire North American Group Inc | 2 | $28 |
| Baxter Healthcare | 1 | $22 |
| Electromed, Inc. | 2 | $20 |
| Shionogi Inc | 1 | $20 |
| Resmed Corp | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Biomerieux Inc | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125,333
- AREXVY$57,896
- OFEV$16,617
- ANORO$12,138
- NUCALA$3,200
- ANORO ELLIPTA$221
- Esbriet$130
How this compares
$327,912 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,874 | $1,373,386 |
| OfevNintedanib Esylate | 17 | $222,788 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 120 | $88,245 |
| NucalaMepolizumab | 19 | $80,130 |
| Breo ElliptaFluticasone/Vilanterol | 152 | $66,590 |
| Incruse ElliptaUmeclidinium Bromide | 144 | $52,790 |
| XifaxanRifaximin | 26 | $41,973 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,156 | $30,060 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $27,366 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 120 | $19,575 |
| EliquisApixaban | 21 | $17,287 |
| JardianceEmpagliflozin | 35 | $17,143 |
| EntrestoSacubitril/Valsartan | 22 | $13,658 |
| Spiriva HandihalerTiotropium Bromide | 20 | $13,426 |
| Ventolin HfaAlbuterol Sulfate | 182 | $12,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $296,891 | $1,604,5812,254 claims |
| Boehringer IngelheimOfev, Jardiance | $24,519 | $239,93152 claims |
| AstraZenecaBreztri Aerosphere, Brilinta | $1,875 | $93,704134 claims |
| PfizerEliquis | $56 | $17,28721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Newark
- Christina MiglioreNewark$91K
- Alfred LardizabalNewark$49K
- Yazan AbdeenNewark$44K
- Pratik PatelNewark$22K
- Thiruvengadam AnandarangamNewark$19K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.